Long‐term health‐related quality of life among men with prostate cancer in the Finnish randomized study of screening for prostate cancer
Open Access
- 4 June 2020
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 9 (15) , 5643-5654
Abstract
Background: The long‐term health‐related quality of life (HRQOL) impacts of PCa screening have not been adequately evaluated. We aimed to compare the generic and disease‐specific health‐related quality of life (HRQOL) among men with prostate cancer in the screening arm with the control arm of the PSA‐based prostate cancer screening trial in up to 15 years of follow‐up.Materials and methods: This study was conducted within population‐based Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC). During 1996‐1999 80,458 men were randomized to the serum prostate‐specific antigen (PSA) screening arm (SA, N = 32 000) and the control arm (CA, N = 48 458). Men in the screening arm were screened at 4‐year intervals until 2007. HRQOL questionnaires were delivered to newly diagnosed prostate cancer patients in the screening and control arm 1996‐2006 (N = 5128) at the time of diagnosis (baseline), at 3‐month, 12‐month and 5, 10, and 15‐year follow‐up. Validated UCLA Prostate Cancer Index (UCLA‐PCI) and RAND 36‐Item Health Survey were used for HRQOL assessment. The data were analyzed with a random effects model for repeated measures.Results: At baseline, men with prostate cancer in the screening arm reported better Sexual Function, as well as less Sexual and Urinary Bother. Long‐term follow‐up revealed slightly higher HRQOL scores in the screening arm in prostate cancer specific measures at 10‐year post diagnosis, but the differences were statistically significant only in Urinary Bother (UCLA‐PCI score 77.9; 95% CI 75.2 to 80.5 vs. 70.9; 95% CI 66.8 to 74.9 P = .005). The generic HRQOL scores were comparable between the trial arms. The overall differences in disease‐specific or generic HRQOL scores by trial arm did not vary during the follow‐up.Conclusion: No major differences were observed in HRQOL in men with prostate cancer between the prostate cancer screening and control arms during five to 15‐year follow‐up.Keywords
Funding Information
- Research Council of Finland (#260931)
This publication has 25 references indexed in Scilit:
- Health-Related Quality of Life in the Finnish Trial of Screening for Prostate CancerEuropean Urology, 2014
- Screening for prostate cancerCochrane Database of Systematic Reviews, 2013
- Health-Related Quality-of-Life Findings for the Prostate Cancer Prevention TrialJNCI: Journal of the National Cancer Institute, 2012
- Quality-of-Life Effects of Prostate-Specific Antigen ScreeningNew England Journal of Medicine, 2012
- Long-Term Disease-Specific Functioning Among Prostate Cancer Survivors and Noncancer Controls in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening TrialJournal of Clinical Oncology, 2012
- Updating and Validating the Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts Using Data From 6 CountriesAmerican Journal of Epidemiology, 2011
- The effect of study arm on prostate cancer treatment in the large screening trial ERSPCInternational Journal of Cancer, 2009
- Lead Time and Overdiagnosis in Prostate-Specific Antigen Screening: Importance of Methods and ContextJNCI: Journal of the National Cancer Institute, 2009
- The Finnish trial of prostate cancer screening: where are we now?BJU International, 2003
- Transitions in health-related quality of life during the first nine months after diagnosis with prostate cancerProstate Cancer and Prostatic Diseases, 1998